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Abstract
Epithelial-mesenchymal plasticity in breast carcinoma encom-
passes the phenotypic spectrum whereby epithelial carcinoma
cells within a primary tumor acquire mesenchymal features and re-
epithelialize to form a cohesive secondary mass at a metastatic
site. Such plasticity has implications in progression of breast
carcinoma to metastasis, and will likely influence response to
therapy. The transcriptional and epigenetic regulation of molecular
and cellular processes that underlie breast cancer and result in
characteristic changes in cell behavior can be monitored using an
increasing array of marker proteins. Amongst these markers exists
the potential for emergent prognostic, predictive and therapeutic
targeting.
Introduction
For almost two decades the prospect that recapitulation of
the developmental process called epithelial to mesenchymal
transition (EMT) may play an important role in carcinoma
progression has been vigorously debated. Evidence of EMT
from model systems supports further investigation of a
potential new process to target the most insidious aspect of
carcinoma - metastatic progression. However, evidence to
demonstrate EMT in vivo has been controversial. We
describe here recent developments in clinical studies along-
side the latest findings from model systems pertinent to
breast cancer progression, which strongly support the exis-
tence of EMT-like changes in breast carcinoma. Figure 1
illustrates examples of EMT processes in development and
cancer. EMT marker expression is associated with poor
prognosis in breast cancer, both at the individual gene
product level and in basal subgroup demographics. Most
importantly, cells isolated from breast carcinoma using
protocols known to enrich for ‘breast cancer stem cells’
(BCSCs), which are dramatically more malignant than their
non-BCSC counterparts, show clear evidence of EMT. The
existence of EMT changes in clinical breast cancer places
EMT at the center of malignancy. While presently there are no
reports of mutations in important EMT regulators driving malig-
nancy or disease progression, ensuing studies may clarify their
involvement. Similarly, the EMT process is only starting to be
specifically targeted for therapeutic benefit, although several
current therapeutic targets are implicated in driving EMT. We
anticipate that the growing acceptance of EMT will bring such
translational advances in the coming years.
Regulation of epithelial cell plasticity during EMT is
increasingly implicated in the progression of carcinoma.
Epithelial cells that undergo EMT lose their epithelial cell
characteristics to acquire a mesenchymal phenotype and
become migratory and invasive. Thus, EMT is characterized
by cellular and molecular changes that include: the loss of
cell-cell adhesion and apical-basal polarity involving E-
cadherin (CDH1) in adherens junctions, occludins (OCLN)
and claudins (CLDN) in tight junctions, and desmoplakin
(DSP) in desmosomes; downregulation of epithelial cyto-
keratins (KRT8, KRT18, and KRT19); upregulation of mesen-
chymal proteins vimentin (VIM) and, in some cases, alpha-
smooth muscle actin (ACTA2); reorganization of cytoskeleton
to acquire more spindle-like morphology; increased motility
and invasiveness involving dynamic actin microfilament
networks; and increased resistance to apoptosis. During
carcinoma progression, epithelial cells detach from the
primary tumor, adhere to and invade the surrounding stroma,
intravasate into blood vessels, and disseminate to distant
tissues and organs where they extravasate and can lead to
secondary tumors. The processes required for metastasis of
epithelial cells from primary tumors closely resembles that of
cells undergoing EMT followed by mesenchymal to epithelial
transition at the site of arrest [1-3].
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Histopathological characterization of breast
cancer
Greater than 95% of breast cancers are of epithelial origin.
Although there are several histological types, primary histo-
pathological analysis of breast carcinoma establishes
whether the lesion is in situ carcinoma (confined to the
glandular component of the breast and distinguished from
benign breast diseases in part by a discontinuous outer myo-
epithelial cell layer, and cytoarchitecture) or invasive carci-
noma, which can be either ductal (located at the junction
between the terminal duct and the lobule) or lobular (within
the breast lobules).
Histopathological grading of the invasive portion of the breast
carcinoma (also known as the histoprognostic index) is a
powerful indicator of prognosis in breast cancer. The index is
based on the analysis of the following three criteria, with each
element given a rank of 1 to 3: evaluation of architecture/
tubule formation, measuring the degree of differentiation, with
1 corresponding to more than 75% glandular structures, 2
between 10 and 75%, and 3 below 10%; anisokaryosis,
measuring the state and size of the nucleus, with 3 corres-
ponding to the largest and most irregular nuclei; and
proliferation assessed by the mitotic index, given the value of
1 for less than 10 mitoses per 10 microscopic fields (400×
magnification), 2 for 11 to 20 mitoses, and 3 for greater than
20 mitoses. In the Nottingham grading system [4], a grade of
I is given for a combined score of 3 to 5, II for 6 to 7, and III
for 8 to 9. That this index is now preferred over the classical
Scarff Bloom Richardson grading system is a strong indicator
of tumor progression reflecting in part the extent of EMT in
the carcinoma component of the tumor, since EMT will
strongly influence the architecture/tubule component.
Breast carcinoma displays histological heterogeneity; epi-
thelial cell plasticity can generate distinct cellular subpopu-
lations that contribute to intratumoral heterogeneity. However,
most tumors display a dominant phenotype that enables
Figure 1
Epithelial to mesenchymal transition processes in development and cancer. (a) Epithelial to mesenchymal transition (EMT) in chicken embryo at the
gastrulation stage. Epiblast cells (EP) delaminate at the primitive streak (PS) and undergo extensive migration before giving rise to different
mesodermal derivatives. (b) EMT in the ontogeny of the neural crest. Neural crest cells (NCC) delaminate from the dorsal neural tube (NT; trunk level
in chicken embryos). (c) EMT in murine mammary carcinoma tumors either in transgenic or fat pad orthotopic tumor implantation models. EMT is one
of the mechanisms allowing solitary cells to reach blood vessels (BV) and intravasate (purple arrow). The involvement of macrophages in the invasion
and intravasation of solitary carcinoma cells is not shown in the schematic diagram. Carcinoma can also invade the stroma (black arrow) through
collective cell migration [87]. (d) EMT in breast ductal carcinoma in situ (CIS) at the microinvasive stage. Arrow points to cells delaminating from the
in situ carcinoma mass. (e) EMT in invasive ductal carcinoma. High grade invasive carcinoma contains single cells among cell clusters. Some cells
can also intravasate blood vessels (not shown) and form a transient interaction with macrophages [82]. An EMT signature is found to be mostly
associated with the basal subtype [28]. (f) EMT in sarcomatoid carcinoma. Sarcoma-like malignant cells (SC) are closely apposed to carcinoma
islands (CA). It is not known whether carcinoma cells can reversibly acquire the sarcoma-like phenotype; however, both subtypes share genetic
alterations and the sarcoma subtype exhibits an EMT signature [88]. Blue cells in the schematic diagrams represent stromal cells.
classification of the tumor. Several subtypes of breast
carcinoma have been identified with different clinical
outcomes and response to therapy. Methods to classify
breast tumors have included histopathology, molecular and
clinical pathology, genetic analysis and gene expression
profiling. Histological and molecular classification of breast
cancer describes at least four different phenotypes: the
normal-like phenotype has an expression profile that is similar
to non-cancerous breast tissue; the luminal phenotype
generally includes tumors that are estrogen receptor-positive,
and express the epithelial makers E-cadherin and KRT8,
KRT18, and KRT19; the estrogen receptor-negative tumor
phenotype overexpresses either the human epidermal growth
factor receptor 2 (ERBB2), or markers characteristic of
myoepithelium of the normal mammary gland, including epi-
dermal growth factor receptor, p63, and basal cytokeratins
KRT14, KRT5/6 and KRT17; these tumors are designated
basal-like [5-7]. The classification of breast tumors is an
important determinant for prognosis and responsiveness to
therapy. The ERBB2 and basal-like phenotypes exhibit
unfavorable prognosis and resistance to therapy, although
the ERBB2 subgroup is well treated with targeted therapy
such as Herceptin, and, paradoxically, the basal-like tumors
show higher initial responses to neoadjuvant chemotherapies
[8,9]. In addition, the basal-like tumors show preferential
relapse to brain and lung [10-12].
Molecular mechanisms of epithelial to
mesenchymal transition
The process of EMT requires coordination of a complex
network of extracellular and intracellular signals involving
factors for initiation and feedback mechanisms for a
continuum of changes that occur within cells during transition
from a less epithelial to more mesenchymal phenotype. EMT
can be induced during in vitro cell culture under the influence
of extracellular matrix components and growth factors, such
as transforming growth factor beta (TGFbeta), scatter
factor/hepatocyte growth factor, fibroblast growth factors,
epithelial growth factor family members and insulin-like
growth factors 1 and 2 [2]. Signal transduction pathways
such as Wnt, Hedgehog, Notch and integrin signaling can
also coordinate EMT programs. A number of transcription
factors induce EMT through transcriptional control of
E-cadherin, including SNAI1 (zinc finger protein snail 1),
SNAI2, ZEB1 (zinc finger E-box-binding homeobox 1), ZEB2,
TWIST, FOXC1 (forkhead box protein 1), FOXC2, TCF3
(transcription factor 3 - also known as E47), and GSC
(homeobox protein goosecoid) [13].
Evidence of epithelial to mesenchymal
transition in breast cancer
Comparisons between evidence from cell lines and
breast tumors
Histopathological characterization of breast carcinoma is
essential to correlate tumor phenotypes with molecular
alterations described in vitro or in animal models of breast
carcinoma. Much of the evidence for a possible role of EMT
in progression of breast cancer has arisen from studies of in
vitro culture of epithelial cell lines. However, EMT has largely
been described as a cell culture phenomenon without direct
clinical evidence or clear molecular markers in breast
carcinoma [14]. The culture of epithelial cells under specific
culture conditions can transform epithelial cells into fibro-
blast-like cells, whereby cells cannot achieve epithelial type
polarity and the culture conditions facilitate dispersal. Another
inherent problem is an absence of markers for EMT as faithful
indicators of the degree to which epithelial cells are engaged
in EMT. Cytokeratin markers commonly used as pathological
identifiers of carcinoma are often downregulated, and an
upregulation of vimentin expression in epithelial cells under-
going EMT is difficult to distinguish from the surrounding
stromal cells [15].
Histological correlates associated with EMT in breast
cancer
Microarray gene expression profiles of patients with breast
cancer suggest that the activation of EMT pathways is
correlated with histological grade. Specifically, upregulation
of genes involved in EMT is associated with poorly differ-
entiated tumors relative to low-grade tumors [16]. Several
factors have been shown to play a role. The metastatic
process is more frequent in patients where cytokeratin-
positive disseminated tumor cells are detected in the bone
marrow [17]. In addition, there is a significant correlation
between the loss of syndecan-1 expression with high grade
tumors and poor relapse-free survival in patients with invasive
ductal breast carcinoma [18]. Laminin 5, expressed in
metaplastic and other basal-like carcinoma, induces aggres-
sive properties in cancer cells, including motility, invasion,
and EMT [19]. Decreased retinoblastoma 1 (RB1) expression
is also associated with high-grade breast adenocarcinoma.
There is a possible relationship between the loss of RB1
function and a less differentiated state, increased prolifera-
tion, and high metastatic potential in patients, which has been
tested using in vitro models of growth factor- and cytokine-
induced EMT in MCF10A human mammary epithelial cells
[20]. Furthermore, RB1 controls expression of E-cadherin;
knockdown of RB1 by small interfering RNA in MCF7 breast
cancer cells disrupts E-cadherin-mediated cell-cell adhesion
and induces a mesenchymal-like phenotype [20]. Another
molecule that has appeared as a histological correlate of
grade and EMT is Stromelysin-3 (MMP11) [21]. Stromelysin-
3 enhanced tumorigenesis in the highly differentiated ‘early
stage’ breast cancer cell lines, as well as breast cancer cell
lines that have already undergone EMT [22]. Elevated
expression of TWIST in breast tumor samples from patients
correlates strongly with high-grade invasive carcinoma and
with chromosome instability to promote an EMT-like transition
that is pivotal for the transformation into an aggressive breast
cancer phenotype [23], consistent with its role in driving
mouse mammary carcinoma cell metastasis [24]. SNAI1
expression is inversely correlated with the degree of tumor
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differentiation and is expressed in infiltrating ductal carcinoma
presenting with lymph node metastases [25]. Further
evidence of the role of SNAI1 as a marker of metastatic
potential is demonstrated by high levels of SNAI1 correlated
with increased risk of breast cancer relapse and local
recurrence in a transgenic mouse model [26]. Histopatho-
logic change associated with EMT is exhibited in primary
breast carcinoma and is correlated with a higher tumor grade,
high mitotic index, and negative estrogen/progesterone-
receptor status [27].
Unsupervised clustering of microarray-based immunohisto-
chemisty profiles of tissues from patients with invasive breast
cancer and carcinosarcoma has shown an EMT signature
[28]. Furthermore, markers commonly associated with EMT
(upregulation of N-cadherin, cadherin-11 and the mesenchymal
markers vimentin and ACTA2, overexpression of the extra-
cellular matrix remodeling and invasion proteins SPARC
(secreted acidic cysteine rich glycoprotein), laminin and
fascin, and downregulation of the epithelial markers E-cadherin
and cytokeratins) segregate with basal-like breast tumors in
patients. Interestingly, gene expression profiles of MCF10A
cells grown under low cell density conditions to simulate EMT
initiation in fibroblastic cells display a differentiation program
characteristic of EMT, which includes upregulation of SNAI2
and vimentin, cytoskeletal reorganization, switching of E-
cadherin to N-cadherin expression, and cytosolic relocaliza-
tion of catenins. These cells also display a basal-like pheno-
type [28]. A ‘poor prognosis’ signature from lung-metastatic
breast cancer cells links Wnt pathways with EMT [29].
Genomic and transcriptomic correlates associated with
EMT in breast cancer
A recent integrated genomic-proteomic approach using com-
parative genomic, transcription profiling, reverse-phase
protein array analysis and sequencing for common breast
cancer mutations has shown that metaplastic breast cancers,
which are characterized by lineage plasticity, display unique
DNA copy number aberrations, increased frequency of
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypep-
tide) mutations, higher phosphorylation of phosphoinositide-3
kinase/AKT pathway phosphorylation sites and altered trans-
criptional profiles compared to common breast cancers [30].
Comparative genotypic analysis of microsatellite markers has
also been used in an attempt to reveal the clonal origins of
epithelial and mesenchymal components of tumors. Approxi-
mately 11% of tumors share a significant number of loss of
heterozygosity markers in the carcinoma and adjacent
stroma [31].
The process of EMT has been implicated in the progression
of carcinoma in situ to invasive breast cancer [32]. In gene
expression profiling studies, ductal carcinoma in situ and
invasive breast carcinoma of the same grade cluster together,
suggesting a common origin [33], and share similar genomic
alterations [34]. In addition, in primary tumor consisting of
evidence of three types of invasion - ductal, squamous, and
sarcomatous - loss of cytokeratin and acquisition of vimentin
and ACTA2 in the sarcomatous component suggests EMT
had occurred in the progression to metaplastic breast
carcinoma. Evidence of EMT in the progression of metaplastic
breast carcinoma was also shown in nodal metastasis of the
ductal component of metaplastic breast carcinoma [35].
Molecular mechanisms implicated in EMT and shown in
breast cancer
Amongst other factors, the inducers of EMT, ZEB and SNAI
downregulate the expression and functional organization of
core polarity complexes. Upregulation of ZEB1 promotes
tumor cell dedifferentiation by repressing master regulators of
epithelial polarity as shown in invasive ductal and lobular
breast carcinoma [36]. Expression of EMT-related genes,
including the EMT-inducing transcription factor FOXC2, has
been associated with the basal-like subtype of basal breast
cancer [28,37]. Basal-like tumors show high expression of
EMT-induced markers (vimentin, ACTA2, N-cadherin,
cadherin-11), SPARC, laminin and fascin, low expression of
E-cadherin [28], and poor prognosis due to increased ability
to form metastases in distal organs compared to other
subtypes of invasive breast carcinoma [5,6]. Interestingly,
although Korsching and colleagues challenged the notion
that the expression of vimentin in breast carcinoma is due to
EMT [38], this has not been supported by studies that
associate markers of EMT in breast carcinoma of the basal
phenotype [28,39-41]. Furthermore, although lobular carcino-
mas have been suggested to display characteristics of EMT
due to their downregulation of E-cadherin and pattern of
invasion, these cancers do not express other additional
markers of EMT [28]. TGFbeta induces similar EMT pheno-
types in NMuMG and BRI-JM01 cell line models of EMT;
however, the proteomes of the two cell lines show only
minimal overlap. The differences may arise from the two cell
lines using different mechanisms to achieve an EMT transition
[42]. More recently, it has been shown that TGFbeta can
induce EMT, although activated Ras in coordination with
TGFbeta-induced EMT is required to confer the tumorigenic
and invasive potential [43]. Interestingly, glycogen synthase
kinase 3 beta, which has previously been shown to regulate
nuclear localization of SNAI2 [44], is correlated with tumor
grade in patients with invasive ductal carcinoma, suggesting
a role for EMT mediators in tumor progression [45].
MicroRNA regulation of epithelial to mesenchymal
transition in breast carcinoma
MicroRNAs (miRNAs) have recently been described as crucial
regulators of EMT and metastasis. The miR-200 family, which
suppresses EMT drivers ZEB1 and ZEB2, is selectively
expressed in the sarcomatous component of metaplastic
breast cancers [46]. In addition, miR-10b is highly expressed
in metastatic breast cancer cells and promotes tumor invasion
and migration in vitro. miR-10b expression, which is regulated
by TWIST, correlates with clinical progression in primary
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breast carcinomas [47]. Upregulation of miR-29a is also seen
in a mesenchymal, metastatic RasXT mammary cell line
compared to epithelial EpRas cells. Furthermore, over-
expression of miR-29a suppressed the expression of
tristetraprolin, a regulator of epithelial polarity and metastasis,
and led to EMT and metastasis in cooperation with oncogenic
Ras signaling. These findings correlate with observations in
samples from breast cancer patients that show enhanced
miR-29a and reduced tristetraprolin levels [48]. These
powerful programmatic regulators are poised to become
important predictive/prognostic markers.
Epithelial to mesenchymal transition in mouse models
of breast carcinoma
Mouse mammary tumor models are a valuable tool for direct
visualization of EMT during cancer progression in vivo. A
number of viral and cellular oncogene-driven mammary tumor
models have been developed, including the whey acidic
protein (WAP)-myc [49], mouse mammary tumor virus
(MMTV)-neu [50] and MMTV-polyoma middle T antigen
(MMTV-PyMT) [51] mouse models of breast cancer. Animal
models have an advantage over in vitro cell lines and studies
of breast cancer tumors from patients because of their ability
to recapitulate the tumor-associated stromal environment and
allow mapping of epithelial and stromal cell fates. Each animal
model has unique molecular, cellular and clinical features that
allow evaluation of different aspects representing some of the
heterogeneity seen in breast cancer. MMTV-neu mammary
tumors form solid tumors with little stroma and are locally
invasive [52], while MMTV-PyMT tumors have more stroma
[53]. The MMTV-PyMT mammary tumor model develops
mammary spindle cell tumors that display EMT character-
istics, whereas spindle cell tumors are not common in human
breast cancer [54]. WAP-myc tumors have abundant stromal
cells that surround the invasive tumors [31]. Comparing
fibroblast-specific protein (FSP; also known as S100A4)-cre
as a reporter of cells engaged in EMT and WAP-cre as a
reporter of the epithelial origin, it was clearly shown that EMT
was most extensive in WAP-myc transgenic mice. They
concluded, however, that Myc required collaboration from
additional molecules to induce EMT, and furthermore, overt
evidence of EMT in both the mouse models and human
tumors was not required for metastasis [31]. Earlier trans-
genic mouse studies showed FSP-green fluorescent protein-
labeled Neu mammary carcinoma cells escaping the primary
tumor to re-epithelialize at the site of metastasis [55].
Ablation of the FSP-expressing cells, using a thymidine
kinase suicide vector system, reduced metastatic potential,
reinforcing the role of EMT in metastasis. Conditional
induction of MMTV-driven Neu expression allows the rever-
sible formation of primary tumors. Interestingly, frequent Neu-
independent relapses are observed in these transgenic mice.
Carcinoma cells from these tumors have acquired a mesen-
chymal phenotype induced by SNAI1 expression [26].
Careful analysis of mouse mammary tumor models shows
that ‘EMT phenotype tumors’, defined as those with dual
expression of epithelial and mesenchymal markers, have
higher metastatic potential than the spindle-like tumors [54].
This is consistent with an emerging view that EMT may result
in hybrid/metastable cells, since increasingly in carcinoma
systems, cells coexpressing both epithelial and mesenchymal
lineage traits are seen (reviewed in [56]).
Several non-transgenic models of breast cancer have also
been used to investigate EMT. Comparative analysis of the
transcriptome of tumors derived from four adenocarcinoma
mammary cell lines differing in their ability to intravasate,
extravasate and metastasize to lung revealed that TWIST
expression correlated with the acquisition of the metastatic
phenotype and its expression was required to accomplish the
full metastatic cascade [57].
Epithelial to mesenchymal transition and breast cancer
stem cells
The BCSC hypothesis suggests that breast cancer is derived
from a single tumor initiating cell with stem-like properties
[58]. There are two pathways that are thought to give rise to
breast carcinoma. The long lived cancer stem cells or the
transit-amplifying cells are the targets for carcinogenesis and
acquire the capacity to self-renew during the carcinogenesis
process. BCSCs are defined as a population of cells with a
CD24(-/lo)CD44(+) phenotype. A higher frequency of stem
cell-like CD24(-/lo)CD44(+) cells is associated with the basal
subtype of breast cancer [28,40]. Cancer cells undergoing
EMT exhibit stem cell-like characteristics. More recently,
metaplastic breast cancers and claudin-low breast cancers
have been shown to be enriched for markers of EMT and
display stem cell characteristics. However, claudin-low breast
cancers are distinct from metaplastic breast cancers as they
do not exhibit PIK3CA, AKT or kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations [30]. The EMT
inducers TGFbeta, SNAI and TWIST confer a stem cell
phenotype in immortalized human mammary epithelial cells
with increased ability to form mammospheres in three-
dimensional culture and ductal outgrowths in xenotransplant
assays [40,59]. In addition, CD24(-/lo)CD44(+) cells isolated
from primary breast carcinoma as well as normal breast show
increased expression of EMT-inducing transcription factors
(TWIST1, FOXC2, SNAI1, ZEB2 (also known as SIP1) and
TWIST2), vimentin and fibronectin compared to
CD24(+)CD44(-) epithelial cells isolated from a more
differentiated carcinoma do not [40]. Recently, it has also
been shown in vivo that CD8 T-cell-mediated immune
response to an epithelial breast cancer led to a tumor
outgrowth consisting of cells that had undergone EMT. These
mesenchymal tumor cells have a CD24(-/lo)CD44(+)
phenotype with characteristics of BCSCs, including potent
tumorigenicity, ability to re-establish an epithelial tumor, and
enhanced resistance to drugs and radiation [60,61].
Cancer cells with stem cell-like characteristics are enriched in
residual tumors following standard chemotherapy [62,63].
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There is a significant increase in the expression of EMT-
related genes in CD24(lo/-)CD44(+) cells from post-treat-
ment biopsies from patients that have received standard
anthracycline-taxane chemotherapy compared to patients
with ERBB2 positive tumors that have undergone treatment
with laptinib, an epidermal growth factor receptor and
ERBB2 inhibitor [63].
Normal and transformed mammary epithelial cells that
undergo EMT exhibit stem cell properties, including the ability
to self-renew and efficiently initiate tumors [40]. This
suggests that EMT may facilitate the generation of cancer
stem cells with mesenchymal and self-renewal properties
required for dissemination and initiation of metastases [64].
While the debate persists over the existence of cancer stem
cells (reviewed in [65]), it is clear that this highly malignant
subpopulation exhibits features consistent with EMT.
EMT in micrometastasis and disseminated/circulating
tumor cells
Breast carcinoma primary tumors disseminate via the lymph
and hematogenous routes. Thus, an essential investigation in
patients is the examination of regional lymph for diagnostic
purposes. In recent years, the sentinel lymph node technique
has been increasingly utilized in an attempt to reduce
morbidity linked to surgical removal of auxiliary nodes.
Patients with less than 1.7 cm tumors are eligible for this
screening.
Micrometastases in lymph nodes are defined as less than
2 mm2, although rare single cells can also be found.
However, the prognostic value of these single cells is not
established, since a considerable proportion of these patients
do not relapse. Independent of auxiliary lymph node
examination, there is an increasing trend to analyze circulating
tumor cells (CTCs) in the peripheral blood. The detection of
isolated carcinoma cells correlates with a higher risk of
relapse. However, the number of cells detected is low, except
in locally advanced cancer or in metastatic cancer. The
number of CTCs before treatment is an independent
predictor of progression-free survival and overall survival in
patients with metastatic breast cancer [66].
An assessment of CTCs is an earlier, more reproducible
indicator of disease status than current imaging methods.
CTCs may be a superior surrogate end point, as they are
highly reproducible and correlate better with overall survival
than do changes determined by traditional radiology
[67,68]. Increased sophistication of the methods to isolate,
quantify and assess CTCs is allowing more detailed
molecular analysis. In a study of 226 patients, Aktas and
colleagues [69] found 62% of CTCs were positive for EMT
markers (TWIST, AKT2, or PIK3CA) and 69% positive for
the stem cell marker ALDH1, and that those with EMT and
ALDH1 expression were more likely not to respond to
therapy.
Although clinically more demanding, the analysis of distant
dissemination in the bone marrow reveals the presence of
micrometastatic disseminated tumor cells, which have a
strong prognostic value. The relative risk associated with
disseminated tumor cells was found to be higher than 2 in a
large European consortium study including 4,700 breast
cancer patients [70]. The relative value of screening blood or
bone marrow has been recently reviewed [71] and clearly
shows an advantage to bone marrow screening, especially
for small tumors. However, the analysis of circulating cells is
particularly relevant in the case of neoadjuvant therapy and
for post-surgery follow-up in locally advanced carcinoma
patients as a means to predict relapses at an earlier stage
than is possible with biomarkers and clinical and imaging
investigations [71].
Disseminated carcinoma cells residing in the bone marrow
are mostly quiescent. It is likely that mechanisms controlling
dormancy play a key role in the long-term maintenance of
these cells in the bone marrow [72,73]. Disseminated tumor
cells were found to be enriched for the CD24(lo/-)CD44(+)
phenotype [74]. Moreover, the EMT driver TWIST was found
to be over-represented in disseminated tumor cells that
persisted in the bone marrow after neoadjuvant chemo-
therapy, and the presence of TWIST-positive cells in the
bone marrow prior to chemotherapy correlated with relapse
[75]. In an attempt to assess the clinical relevance of bone
marrow micrometastases, bone marrow samples from a large
cohort of patients were analyzed according to the different
morphological features of cytokeratin-positive cells. This
analysis showed that the frequency of bona fide isolated
carcinoma cells was lower than in previous reports; however,
such cells are detected in patients with low grade tumors of
less than 2 cm [17]. It is noteworthy that sentinel lymph node
micrometastases (between 0.2 and 2 mm) is not correlated
with bone marrow micrometastases (single cells) [76]. These
studies provide additional evidence for very early dissemina-
tion of isolated tumor cells in the bone marrow [77], and this
mechanism operates independently of lymphatic dissemina-
tion. The presence of micrometastatic tumor cells in the bone
marrow in stage IV breast cancer patients correlates with the
presence of bone matrix metastasis and local relapse
[17,78].
A critical issue in demonstrating EMT in breast carcinoma has
been to show evidence of EMT in the primary tumor leading
to isolated invasive cells that could potentially disseminate.
These studies have been performed in transgenic models of
breast carcinoma driven by the PyMT antigen. Multiphotonic
imaging revealed that carcinoma cells dissociate from the
primary tumors at sites of interaction with peritumoral
macrophages. These single carcinoma cells will eventually be
guided toward the neighboring vessels and can be detected
throughout their migration and during intravasation. This
mechanism is driven by a paracrine loop between peri-
vascular macrophages and tumor cells [79-81].
Breast Cancer Research    Vol 11 No 6 Tomaskovic-Crook et al.
Page 6 of 10
(page number not for citation purposes)
Tumor cells produce CSF1 (colony stimulating factor 1),
promoting the recruitment of macrophages that, in turn,
produce epithelial growth factor, which acts as a motogen on
carcinoma cells. A detailed signaling pathway has been
described leading to the formation of lamellipodia through
increased expression of Mena, which inhibits actin
microfilament capping, N-WASP, which induces ACTR2/3
(actin-related protein 2/3) branched actin formation, and
cofilin, a severin protein allowing fast remodeling of actin
microfilaments. Mena is detected at the invasive leading edge
of tumor cells. Based on these findings, an
immunohistochemical pilot study was carried out on tissue
sections from patients with non-metastatic breast carcinoma
tumor and from patients whose primary cancers eventually
metastasized. Using three antibodies to characterize blood
vessels (anti-CD31), macrophages (anti-CD68) and
migratory cancer cells (anti-Mena), a clear cut correlation was
found between the metastatic status and the presence of
interacting cancer cells, macrophages and endothelial cells at
sites of intravasation [82]. Importantly, this study is one of the
first to functionally demonstrate the presence of EMT cells
intravasating in blood vessels within primary tumors.
Epithelial to mesenchymal transition and
chemotherapeutic resistance
EMT is implicated in the progression to distant metastatic
disease and therapeutic resistance. Studies on NMuMG and
EpH4 murine mammary epithelial cell lines have shown
resistance to UV-induced apoptosis following TGFbeta-
induced EMT [83]. Similarly, downregulation of let-7 miRNA
in breast cancer cell lines increases tumor metastasis and
therapeutic resistance, and results in stem cell-like charac-
teristics and an EMT-related gene expression profile [62]. It
was recently suggested that metaplastic breast cancer and
claudin-low tumors, which display EMT and stem cell-like
features, may arise from a more chemoresistant breast tumor
than basal-like or luminal breast tumors [30].
Chemotherapeutic agents can also enhance the malignancy
of carcinoma. Following Adriamycin treatment of MCF7 cells,
TWIST1 expression and its interaction with p53-MDM2 is
induced and only cells undergoing Adriamycin-induced EMT
display enhanced invasion and multidrug resistance. TWIST1
depletion by RNA interference blocked mesenchymal trans-
formation, partially reversed multidrug resistance, and
abolished invasion induced by Adriamycin. Furthermore,
TWIST1 RNA interference may show efficacy in Adriamycin-
based chemotherapies for breast cancer [63].
Resistance to ERBB2 targeted therapy is a clinical problem
that may undermine the success of ERBB2 targeted
therapies such as trastuzumab and lapatinib. The ERBB2
pathway may play an important role in the maintenance of
BCSCs. Induction of EMT in BCSCs may be at the root of
resistance of ERBB2 targeted therapy [84]. More generally,
breast cancer cells may acquire resistance to conventional
and targeted therapies upon conversion to a mesenchymal-
like phenotype. A recent high throughput screen using
transformed human breast cells that were experimentally
transformed into mesenchymal cells showed that these cells,
which exhibit cancer stem cell properties, are more resistant
to conventional chemotherapeutic drugs such as paclitaxel or
doxorubicin [85]. Drugs that specifically affect the mesen-
chymal transformed cells and not the transformed epithelial
line were selected. From a screen of 16,000 compounds,
several compounds, including salinomycin, were identified to
have selective cytotoxity toward enriched breast cancer stem
cells. This pioneer study provides a proof of principle that
cancer stem cells exhibiting EMT features can be selectively
targeted by drugs. However, it is anticipated that even such
drugs can induce resistance during treatment. Thus, it is
essential that new strategies use combined therapies to
interfere with EMT pathways [86].
Conclusion
This review summarizes evidence for the growing implication
of EMT in the progression of breast carcinoma, both in
murine models and in humans. However, there is an urgent
need for new surrogate markers to define different stages
during the transition from the epithelial to mesenchymal
phenotype, and the reverse transition. These markers may
differ from those expressed by normal-like epithelial cells
undergoing EMT. A relevant example is the well described
presence of micrometastatic carcinoma cells in the blood and
bone marrow that retain cytokeratin expression, and the
implication of ‘hybrid’ cells in several systems. However,
capturing the mesenchymal phenotype in primary tumors and
metastases may prove to be a difficult task, due to the slow
growth kinetics of tumors, resulting in an extended period
before a mesenchymal to epithelial transition mechanism
occurs. The unique topology of tumor growth in the colon has
permitted the observation of rare pioneer isolated carcinomas
and their likelihood to reconstitute epithelial-like glandular
structures. Preliminary evidence indicates that such cells may
exist in primary breast cancer, although their detection would
require simultaneous labeling using three antibodies to
visualize carcinoma cells in contact with endothelial cells and
macrophages.
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